Clinical Trial Update: A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas [Phase 3]

View source ↗

Summary

Phase 3 study evaluating a 3-month course of ulipristal acetate for abnormal uterine bleeding due to leiomyomas; completed with posted results in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Abnormal Uterine Bleeding
• Leiomyoma

Drugs mentioned

• Ulipristal acetate (ulipristal acetate)

Snippet

Sponsor: Allergan | Conditions: Leiomyoma, Uterine Hemorrhage | Phase 3 | Status: COMPLETED | Results posted: 2019-04-05